<p>一周前，<strong>GRAIL, Inc.</strong>（纳斯达克代码：GRAL）发布了一组强劲的第一季度财报，可能会导致该股票的重新评级。收入和每股亏损均好于预期，收入为 4100 万美元，比预期高出 4.2%。法定亏损小于分析师的预期，每股亏损为 2.29 美元。在结果公布后，分析师们更新了他们的盈利模型，了解他们是否认为公司的前景发生了重大变化，或者一切如常，将会很有帮助。因此，我们收集了最新的财报后预测，以查看估计值对明年的展望。</p>
<p>特朗普承诺要&#34;释放&#34;美国的石油和天然气，这 15 只美国股票的发展将受益。</p>
<p>考虑到最新的结果，来自八位分析师的最新共识是，GRAIL 在 2026 年的收入为 1.814 亿美元。如果实现，这将意味着其收入较过去 12 个月增长 16%。每股亏损预计将大幅上升，达到 10.72 美元。在这份最新报告之前，市场共识预计收入为 1.803 亿美元，每股亏损为 11.08 美元。看起来最近的更新中情绪略有上升，分析师们对每股亏损的预测变得更加乐观，尽管收入数字没有变化。</p>
<p>查看我们对 GRAIL 的最新分析</p>
<p>平均目标价保持在 68.57 美元，似乎表明业务表现符合预期。查看分析师估计的范围，以评估不同意见与均值的差异也很有启发性。对 GRAIL 的看法存在一些差异，最乐观的分析师将其估值为 82.00 美元，而最悲观的分析师则为每股 56.00 美元。这些目标价显示分析师对该业务有不同的看法，但估计值的差异不足以表明有人在押注于极大的成功或彻底的失败。</p>
<p>当然，另一种看待这些预测的方法是将其与行业本身进行对比。我们要强调的是，GRAIL 的收入增长预计将放缓，预计到 2026 年底的年化增长率为 22%，远低于过去五年 35% 的历史年增长率。与该行业中 552 家有分析师覆盖的其他公司相比，后者预计每年收入增长 21%。因此，很明显，尽管 GRAIL 的收入增长预计将放缓，但其增长预计大致与行业持平。</p>
<h2>结论</h2>
<p>最明显的结论是，分析师对明年的亏损预测没有做出任何更改。他们还重新确认了收入预估，预计公司将以与更广泛行业相似的速度增长。共识目标价保持在 68.57 美元，最新的估计不足以对他们的目标价产生影响。</p>
<p>考虑到这一点，我们不会过于急于对 GRAIL 下结论。长期的盈利能力远比明年的利润更为重要。在 Simply Wall St，我们有 GRAIL 到 2028 年的全系列分析师估计，您可以在我们的平台上免费查看。</p>
<p>您仍然需要注意风险，例如——GRAIL 有 <strong>5 个警告信号</strong>（其中 2 个是显著的），我们认为您应该了解。</p>

GRAL

纽交所高增长板生物技术指数 ETF - First Trust

生物科技 ETF - VanEck Vectors

<p>GRAIL, Inc.（纳斯达克代码：GRAL）报告了强劲的第一季度业绩，收入为 4100 万美元，超出预期 4.2%，每股亏损为 2.29 美元，低于预期。分析师已更新其预测，预计 2026 年收入为 1.814 亿美元，增长 16%，而每股亏损预计将上升至 10.72 美元。共识目标价维持在 68.57 美元，反映出业务表现稳定。预计 GRAIL 的收入增长将放缓，但与行业趋势保持一致。分析师表示谨慎乐观，指出亏损预测和收入预估没有显著变化</p>

<p>A week ago, <strong>GRAIL, Inc.</strong> (NASDAQ:GRAL) came out with a strong set of first-quarter numbers that could potentially lead to a re-rate of the stock. Revenues and losses per share were both better than expected, with revenues of US$41m leading estimates by 4.2%. Statutory losses were smaller than the analystsexpected, coming in at US$2.29 per share. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.</p>
<div class="lb-trans"><p>一周前，<strong>GRAIL, Inc.</strong>（纳斯达克代码：GRAL）发布了一组强劲的第一季度财报，可能会导致该股票的重新评级。收入和每股亏损均好于预期，收入为 4100 万美元，比预期高出 4.2%。法定亏损小于分析师的预期，每股亏损为 2.29 美元。在结果公布后，分析师们更新了他们的盈利模型，了解他们是否认为公司的前景发生了重大变化，或者一切如常，将会很有帮助。因此，我们收集了最新的财报后预测，以查看估计值对明年的展望。</p>
</div><p>Trump has pledged to &#34;unleash&#34; American oil and gas and these 15 US stocks have developments that are poised to benefit.</p>
<div class="lb-trans"><p>特朗普承诺要&#34;释放&#34;美国的石油和天然气，这 15 只美国股票的发展将受益。</p>
</div><p>Taking into account the latest results, the most recent consensus for GRAIL from eight analysts is for revenues of US$181.4m in 2026. If met, it would imply a solid 16% increase on its revenue over the past 12 months. Per-share losses are supposed to see a sharp uptick, reaching US$10.72. Before this latest report, the consensus had been expecting revenues of US$180.3m and US$11.08 per share in losses. It looks like there's been a modest increase in sentiment in the recent updates, with the analysts becoming a bit more optimistic in their predictions for losses per share, even though the revenue numbers were unchanged.</p>
<div class="lb-trans"><p>考虑到最新的结果，来自八位分析师的最新共识是，GRAIL 在 2026 年的收入为 1.814 亿美元。如果实现，这将意味着其收入较过去 12 个月增长 16%。每股亏损预计将大幅上升，达到 10.72 美元。在这份最新报告之前，市场共识预计收入为 1.803 亿美元，每股亏损为 11.08 美元。看起来最近的更新中情绪略有上升，分析师们对每股亏损的预测变得更加乐观，尽管收入数字没有变化。</p>
</div><p>See our latest analysis for GRAIL</p>
<div class="lb-trans"><p>查看我们对 GRAIL 的最新分析</p>
</div><p>The average price target held steady at US$68.57, seeming to indicate that business is performing in line with expectations. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on GRAIL, with the most bullish analyst valuing it at US$82.00 and the most bearish at US$56.00 per share. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure.</p>
<div class="lb-trans"><p>平均目标价保持在 68.57 美元，似乎表明业务表现符合预期。查看分析师估计的范围，以评估不同意见与均值的差异也很有启发性。对 GRAIL 的看法存在一些差异，最乐观的分析师将其估值为 82.00 美元，而最悲观的分析师则为每股 56.00 美元。这些目标价显示分析师对该业务有不同的看法，但估计值的差异不足以表明有人在押注于极大的成功或彻底的失败。</p>
</div><p>Of course, another way to look at these forecasts is to place them into context against the industry itself. We would highlight that GRAIL's revenue growth is expected to slow, with the forecast 22% annualised growth rate until the end of 2026 being well below the historical 35% p.a. growth over the last five years. Compare this to the 552 other companies in this industry with analyst coverage, which are forecast to grow their revenue at 21% per year. So it's pretty clear that, while GRAIL's revenue growth is expected to slow, it's expected to grow roughly in line with the industry.</p>
<div class="lb-trans"><p>当然，另一种看待这些预测的方法是将其与行业本身进行对比。我们要强调的是，GRAIL 的收入增长预计将放缓，预计到 2026 年底的年化增长率为 22%，远低于过去五年 35% 的历史年增长率。与该行业中 552 家有分析师覆盖的其他公司相比，后者预计每年收入增长 21%。因此，很明显，尽管 GRAIL 的收入增长预计将放缓，但其增长预计大致与行业持平。</p>
</div><h2>The Bottom Line</h2>
<div class="lb-trans"><h2>结论</h2>
</div><p>The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. The consensus price target held steady at US$68.57, with the latest estimates not enough to have an impact on their price targets.</p>
<div class="lb-trans"><p>最明显的结论是，分析师对明年的亏损预测没有做出任何更改。他们还重新确认了收入预估，预计公司将以与更广泛行业相似的速度增长。共识目标价保持在 68.57 美元，最新的估计不足以对他们的目标价产生影响。</p>
</div><p>With that in mind, we wouldn't be too quick to come to a conclusion on GRAIL. Long-term earnings power is much more important than next year's profits. At Simply Wall St, we have a full range of analyst estimates for GRAIL going out to 2028, and you can see them free on our platform here..</p>
<div class="lb-trans"><p>考虑到这一点，我们不会过于急于对 GRAIL 下结论。长期的盈利能力远比明年的利润更为重要。在 Simply Wall St，我们有 GRAIL 到 2028 年的全系列分析师估计，您可以在我们的平台上免费查看。</p>
</div><p>You still need to take note of risks, for example - GRAIL has <strong>5 warning signs</strong> (and 2 which are significant) we think you should know about.</p>
<div class="lb-trans"><p>您仍然需要注意风险，例如——GRAIL 有 <strong>5 个警告信号</strong>（其中 2 个是显著的），我们认为您应该了解。</p>
</div>

Here's What Analysts Are Forecasting For GRAIL, Inc. (NASDAQ:GRAL) After Its First-Quarter Results

Simplywall

GRAIL

基因改革 ETF - ARK

纳斯达克生物科技指数 ETF - iShares Nasdaq

基因免疫&健康关怀 ETF - iShares

2 倍做多纳斯达克生物技术 ETF - ProShares

标普生物技术 3 倍做多 - Direxion

标普生物技术 ETF - SPDR

医疗业 ETF - SPDR

动态生物技术与基因组 ETF - Invesco

医药突破 ETF - ALPS

以下是分析师在 GRAIL 公司（NASDAQ: GRAL）公布第一季度业绩后的预测